Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Elie Traer,Eytan M Stein,Mona Stefanos,John C Byrd,Alice S Mims,Christopher R Cogle,Robert L Redner,Maria R Baer,Mark R Litzow,Wendy Stock,Rebecca L Olin,Tara L Lin,Uma Borate,Abigail B Shoben,Amy Burd,Tibor Kovacsovics,Ying Huang,William Blum,Ross L Levine,Nyla A Heerema,Sonja Marcus,Franchesca Druggan,Leonard Rosenberg,Gary J Schiller,Matthew C Foster,James M Foran,Martha Arellano ,Michael Boyiadzis ,Theophilus J Gana ,Ronan T Swords ,Jo‐Anne Vergilio ,Robert H Collins ,Zeina Al‐Mansour ,Timothy Chen ,Ashley Owen Yocum ,Brian J Druker ,Prapti A Patel

doi:10.1182/blood-2021-148207

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Elie Traer, Eytan M Stein + Show 35 more

Open Access

https://doi.org/10.1182/blood-2021-148207

Copy DOI

#Research Funding #Equity Holder In Publicly-traded Company + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Full Text